SCHEMBL5543072

SCHEMBL5543072

[O]CC/C=C/c1cccc(Cl)c1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 1/20 0.40
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
PPP1R15A O75807 1/20 0.38
MELK Q14680 1/20 0.38
PPP1R15B Q5SWA1 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
ALDH1A1 P00352 5/20 0.36
LMNA P02545 4/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TAAR1 Q96RJ0 1/20 0.36
PNMT P11086 1/20 0.35
TSHR P16473 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543074 1.00 PTGS2 (0.40) PTGS2HDAC4HDAC1L3MBTL1PPP1R15A
SCHEMBL5541843 0.89 PTGS2 (0.38) PTGS2HDAC4HDAC1L3MBTL1PPP1R15A
SCHEMBL5541838 0.89 PTGS2 (0.38) PTGS2HDAC4HDAC1L3MBTL1PPP1R15A
SCHEMBL5542399 0.88 PTGS2 (0.38) PTGS2HDAC4HDAC1L3MBTL1PPP1R15A
SCHEMBL5542402 0.88 PTGS2 (0.38) PTGS2HDAC4HDAC1L3MBTL1PPP1R15A
SCHEMBL2094926 0.85 PTGS2 (0.42) PTGS2HDAC4HDAC1L3MBTL1PPP1R15A
SCHEMBL2094928 0.85 PTGS2 (0.42) PTGS2HDAC4HDAC1L3MBTL1PPP1R15A
SCHEMBL5846838 0.80 PTGS2 (0.43) PTGS2HDAC4HDAC1KMT2AMEN1
SCHEMBL5846843 0.80 PTGS2 (0.43) PTGS2HDAC4HDAC1KMT2AMEN1
SCHEMBL2092517 0.79 PTGS2 (0.41) PTGS2HDAC4HDAC1L3MBTL1PPP1R15A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 PTGS2 3418/4885HDAC4 707/4885HDAC1 322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.